Neurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Dec. 01, 2016 --

What:  
Neurocrine Biosciences (Nasdaq:NBIX), a company that discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Kevin Gorman, Ph.D., President & Chief Executive Officer, will ring the Opening Bell. 

Where: 
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When: 
Friday, December 2, 2016 – 9:15 a.m. to 9:30 a.m. ET    

Neurocrine Biosciences Media Contact: 
Jane Sorensen
(858) 617-7653 
[email protected]

Nasdaq MarketSite: 
Emily Pan
(646) 441-5120 
[email protected]

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media: 
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: 
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page: 
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page: 
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page: 
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page: 
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About Neurocrine Biosciences 
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and INGREZZA (valbenazine or NBI-98854), a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine plans to commercialize INGREZZA in the United States upon approval by the FDA.

About Nasdaq 
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com  

-NDAQA-